Similarly, Responder breast tumors exhibited progressive suppression of a GI, calculated as the ratio between Ki-67 immunoreactivity and cleaved caspase-3 in response to doxorubicin treatment (24) (Figure 2D). This evidence concerns the gene MKI67 and breast neoplasm.